FORE Biotherapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced that the Company, will participate at the following investor conferences:

• Oppenheimer 34^th Annual Healthcare Life Sciences Conference. The presentation will take place on Wednesday, February 14 from 8:00 a.m. - 8:30 a.m. ET
• Evercore ISI’s 2024 Emerging Private Biotech Conference. The presentation will take place on Wednesday, February 28 from 1:05 p.m. – 1:35 p.m. ET

Shawn M. Leland, PharmD, RPh, Interim Chief Executive Officer, and Jeffrey Sacher, Interim Chief Financial Officer, will host and participate in one-on-one meetings. Please contact Argot Partners to schedule one-on-one meetings with the management team.

About Fore Biotherapeutics

Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; PLX8394) is an inhibitor of BRAF dimerization allowing for the targeting of V600 and non-V600 driven tumors. In Phase 1/2a, plixorafenib demonstrated deep and durable responses in V600-mutated MAPK inhibitor-naïve patients, including a 42% overall response in patients with solid tumors with a median duration of response of 17.8 months and a 67% overall response rate in patients with primary central nervous system tumors with a median duration of response of 13.9 months. Plixorafenib is currently being investigated in the ongoing, potentially registrational Phase 2 FORTE study. For more information, please visit www.fore.bio or follow us on X (formerly Twitter) and LinkedIn.